HSCS — Heart Test Laboratories Share Price
Last trade - 00:00- $2.39m
- -$4.19m
- $0.01m
- 26
- 30
- 24
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.4 | ||
| Price to Tang. Book | 0.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 185.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -66.24% | ||
| Return on Equity | -152.61% | ||
| Operating Margin | -32390.54% | ||
Financial Summary
| Year End 30th Apr | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.06 | 0.03 | 0.01 | 0.01 | 0.06 | 1.9 | -56.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Heart Test Laboratories, Inc., doing business as HeartSciences, is an artificial intelligence electrocardiogram (AI ECG) company. The Company is focused on using AI to transform ECG to save lives through earlier detection of heart disease. The Company’s initial focus is on applying technology to extend the clinical indications for use of an electrocardiograph (ECG) device. Its first device, the MyoVista is an ECG that can be used in a range of clinical settings and provides diagnostic information to a qualified healthcare professional on cardiac dysfunction which has traditionally only been provided using cardiac imaging. In addition, MyoVista provides conventional ECG information. The Company focuses on marketing its device both domestically and internationally to various hospitals, clinics, and medical centers and manufacturing the devices using outsourced production facilities.
Directors
- Last Annual
- April 30th, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- August 16th, 2007
- Public Since
- June 15th, 2022
- No. of Shareholders
- 311
- No. of Employees
- 12
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 655,616
- Address
- 550 Reserve St, Suite 360, SOUTHLAKE, 76092
- Web
- https://heartsciences.com/
- Phone
- +1 6822377781
- Auditors
- Haskell & White LLP
Similar to HSCS
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
FAQ
As of Today at 21:04 UTC, shares in Heart Test Laboratories are trading at $5.25. This share price information is delayed by 15 minutes.
Shares in Heart Test Laboratories last closed at $5.25 and the price had moved by -94.47% over the past 365 days. In terms of relative price strength the Heart Test Laboratories share price has underperformed the S&P500 Index by -95.6% over the past year.
The overall consensus recommendation for Heart Test Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Heart Test Laboratories does not currently pay a dividend.
Heart Test Laboratories does not currently pay a dividend.
Heart Test Laboratories does not currently pay a dividend.
To buy shares in Heart Test Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.25, shares in Heart Test Laboratories had a market capitalisation of $3.44m.
Here are the trading details for Heart Test Laboratories:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HSCS
Based on an overall assessment of its quality, value and momentum Heart Test Laboratories is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Heart Test Laboratories is $67.50. That is 1185.71% above the last closing price of $5.25.
Analysts covering Heart Test Laboratories currently have a consensus Earnings Per Share (EPS) forecast of -$20.00 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Heart Test Laboratories. Over the past six months, its share price has underperformed the S&P500 Index by -73.48%.
As of the last closing price of $5.25, shares in Heart Test Laboratories were trading -73.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Heart Test Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Heart Test Laboratories' directors